Caprelsa (vandetanib): Restriction of indication

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Caprelsa
Active substance
Vandetanib
Therapeutic area (MeSH)
Thyroid Neoplasms
Procedure number
EMEA/H/C/002315/II/0043
Regulatory outcome
Variation
DHPC type
Restriction of indication
Human ATC code
L01XE

How useful was this page?

Add your rating